CL2016002515A1 - Quinazolin-thf-aminas halogenadas como inhibidores de pde1. - Google Patents
Quinazolin-thf-aminas halogenadas como inhibidores de pde1.Info
- Publication number
- CL2016002515A1 CL2016002515A1 CL2016002515A CL2016002515A CL2016002515A1 CL 2016002515 A1 CL2016002515 A1 CL 2016002515A1 CL 2016002515 A CL2016002515 A CL 2016002515A CL 2016002515 A CL2016002515 A CL 2016002515A CL 2016002515 A1 CL2016002515 A1 CL 2016002515A1
- Authority
- CL
- Chile
- Prior art keywords
- quinazolin
- pde1
- inhibitors
- thf
- halogenated amines
- Prior art date
Links
- 101100243084 Dictyostelium discoideum pdsA gene Proteins 0.000 title 1
- 101100243086 Schizosaccharomyces pombe (strain 972 / ATCC 24843) cgs2 gene Proteins 0.000 title 1
- 150000001412 amines Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
COMPUESTOS DERIVADOS DE QUINAZOLIN-TETRAHIDROFURAN-AMINAS HALOGENADAS, COMO INHIBIDORES DE PDE1; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE, UTIL PARA EL TRATAMIENTO DE TRASTORNO POR DEFICIT DE ATENCION CON HIPERACTIVIDAD (TDAH).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201400194 | 2014-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016002515A1 true CL2016002515A1 (es) | 2016-12-16 |
Family
ID=52779655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016002515A CL2016002515A1 (es) | 2014-04-04 | 2016-10-03 | Quinazolin-thf-aminas halogenadas como inhibidores de pde1. |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US10005764B2 (es) |
| EP (1) | EP3126354B1 (es) |
| JP (1) | JP6554116B2 (es) |
| KR (1) | KR20160138084A (es) |
| CN (2) | CN106132953B (es) |
| AP (1) | AP2016009521A0 (es) |
| AR (1) | AR101155A1 (es) |
| AU (1) | AU2015239696B2 (es) |
| CA (1) | CA2943011A1 (es) |
| CL (1) | CL2016002515A1 (es) |
| CR (1) | CR20160463A (es) |
| CY (1) | CY1122784T1 (es) |
| DK (1) | DK3126354T3 (es) |
| DO (1) | DOP2016000263A (es) |
| EA (1) | EA032579B1 (es) |
| EC (1) | ECSP16082599A (es) |
| ES (1) | ES2776359T3 (es) |
| GE (1) | GEP20186920B (es) |
| GT (1) | GT201600213A (es) |
| HR (1) | HRP20200369T1 (es) |
| IL (1) | IL248078B (es) |
| JO (1) | JO3628B1 (es) |
| LT (1) | LT3126354T (es) |
| MA (1) | MA39837B1 (es) |
| MX (1) | MX364519B (es) |
| PE (1) | PE20161380A1 (es) |
| PH (1) | PH12016501938A1 (es) |
| PL (1) | PL3126354T3 (es) |
| PT (1) | PT3126354T (es) |
| RS (1) | RS60017B1 (es) |
| RU (1) | RU2692808C2 (es) |
| SG (1) | SG11201608190YA (es) |
| SI (1) | SI3126354T1 (es) |
| SM (1) | SMT202000132T1 (es) |
| SV (1) | SV2016005297A (es) |
| TW (1) | TWI664178B (es) |
| UA (1) | UA119166C2 (es) |
| WO (1) | WO2015150254A1 (es) |
| ZA (1) | ZA201606566B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA39837B1 (fr) | 2014-04-04 | 2020-05-29 | H Lundbeck As | Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1 |
| KR102590848B1 (ko) | 2016-12-28 | 2023-10-19 | 다트 뉴로사이언스, 엘엘씨 | Pde2 억제제로서 치환된 피라졸로피리미디논 화합물 |
| CA3120971A1 (en) | 2017-11-27 | 2019-05-31 | Dart Neuroscience, Llc | Substituted furanopyrimidine compounds as pde1 inhibitors |
| EP3802545A4 (en) | 2018-05-25 | 2022-03-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN117105809B (zh) * | 2023-10-20 | 2024-05-03 | 中国农业大学 | 一种苯甲酰苯胺化合物及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10042058A1 (de) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| GB0229281D0 (en) * | 2002-12-16 | 2003-01-22 | Novartis Ag | Organic compounds |
| ZA200507979B (en) * | 2003-03-03 | 2007-03-28 | Vertex Pharma Inc | Quinazolines useful as modulators of ion channels |
| GB0327319D0 (en) * | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| US20060019975A1 (en) * | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| US20090023756A1 (en) * | 2006-02-23 | 2009-01-22 | Pfizer Inc | Substituted quinazolines as pde10 inhibitors |
| US20070265258A1 (en) * | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
| WO2011036074A1 (en) * | 2009-09-24 | 2011-03-31 | Basf Se | Aminoquinazoline compounds for combating invertebrate pests |
| US20130116241A1 (en) * | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| TW201609713A (zh) | 2013-12-19 | 2016-03-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺 |
| TW201611834A (en) * | 2014-02-07 | 2016-04-01 | Lundbeck & Co As H | Hexahydrofuropyrroles as PDE1 inhibitors |
| TW201625605A (zh) | 2014-04-04 | 2016-07-16 | 賽諾菲公司 | 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類 |
| MA39837B1 (fr) | 2014-04-04 | 2020-05-29 | H Lundbeck As | Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1 |
| AR099937A1 (es) | 2014-04-04 | 2016-08-31 | Sanofi Sa | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| SG11201608108SA (en) | 2014-04-04 | 2016-10-28 | Hoffmann La Roche | Pyridine-2-amides useful as cb2 agonists |
| BR112016023117B1 (pt) | 2014-04-04 | 2023-02-07 | Pfizer Inc | Compostos de heteroarila ou arila bicíclicos fundidos |
| AU2015239537B2 (en) | 2014-04-04 | 2019-04-04 | Eidgenoessische Technische Hochschule Zuerich | 5,6-disubstituted pyridine-2-carboxamides as Cannabinoid receptor agonists |
-
2015
- 2015-03-27 MA MA39837A patent/MA39837B1/fr unknown
- 2015-03-27 ES ES15713186T patent/ES2776359T3/es active Active
- 2015-03-27 CA CA2943011A patent/CA2943011A1/en not_active Abandoned
- 2015-03-27 EA EA201691773A patent/EA032579B1/ru not_active IP Right Cessation
- 2015-03-27 KR KR1020167027262A patent/KR20160138084A/ko not_active Ceased
- 2015-03-27 AP AP2016009521A patent/AP2016009521A0/en unknown
- 2015-03-27 US US15/301,210 patent/US10005764B2/en active Active
- 2015-03-27 GE GEAP201514286A patent/GEP20186920B/en unknown
- 2015-03-27 UA UAA201610191A patent/UA119166C2/uk unknown
- 2015-03-27 CR CR20160463A patent/CR20160463A/es unknown
- 2015-03-27 MX MX2016012955A patent/MX364519B/es active IP Right Grant
- 2015-03-27 WO PCT/EP2015/056713 patent/WO2015150254A1/en active Application Filing
- 2015-03-27 DK DK15713186.3T patent/DK3126354T3/da active
- 2015-03-27 PL PL15713186T patent/PL3126354T3/pl unknown
- 2015-03-27 EP EP15713186.3A patent/EP3126354B1/en active Active
- 2015-03-27 PT PT157131863T patent/PT3126354T/pt unknown
- 2015-03-27 RU RU2016138743A patent/RU2692808C2/ru active
- 2015-03-27 LT LTEP15713186.3T patent/LT3126354T/lt unknown
- 2015-03-27 SI SI201531112T patent/SI3126354T1/sl unknown
- 2015-03-27 PE PE2016001906A patent/PE20161380A1/es unknown
- 2015-03-27 JP JP2016560728A patent/JP6554116B2/ja active Active
- 2015-03-27 SG SG11201608190YA patent/SG11201608190YA/en unknown
- 2015-03-27 CN CN201580017454.2A patent/CN106132953B/zh active Active
- 2015-03-27 RS RS20200239A patent/RS60017B1/sr unknown
- 2015-03-27 SM SM20200132T patent/SMT202000132T1/it unknown
- 2015-03-27 AU AU2015239696A patent/AU2015239696B2/en not_active Ceased
- 2015-03-27 CN CN201910110735.2A patent/CN109999039A/zh active Pending
- 2015-03-30 JO JOP/2015/0058A patent/JO3628B1/ar active
- 2015-03-31 TW TW104110439A patent/TWI664178B/zh not_active IP Right Cessation
- 2015-04-01 AR ARP150101009A patent/AR101155A1/es unknown
-
2016
- 2016-09-22 ZA ZA2016/06566A patent/ZA201606566B/en unknown
- 2016-09-27 DO DO2016000263A patent/DOP2016000263A/es unknown
- 2016-09-27 IL IL248078A patent/IL248078B/en active IP Right Grant
- 2016-09-29 PH PH12016501938A patent/PH12016501938A1/en unknown
- 2016-10-03 GT GT201600213A patent/GT201600213A/es unknown
- 2016-10-03 CL CL2016002515A patent/CL2016002515A1/es unknown
- 2016-10-03 SV SV2016005297A patent/SV2016005297A/es unknown
- 2016-10-20 EC ECIEPI201682599A patent/ECSP16082599A/es unknown
-
2018
- 2018-06-13 US US16/007,561 patent/US10526319B2/en active Active
-
2020
- 2020-03-04 HR HRP20200369TT patent/HRP20200369T1/hr unknown
- 2020-03-04 CY CY20201100196T patent/CY1122784T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
| CL2019001224A1 (es) | Composiciones de células t con car anti--bcma. | |
| CL2016003398A1 (es) | Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo. | |
| CL2016003246A1 (es) | Compuestos de dihidroisoquinolinona sustituida | |
| ECSP17044494A (es) | Receptores de antígenos quiméricos de bcma | |
| CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| CO2018005381A2 (es) | Inhibidores éster de acc y usos de los mismos | |
| CL2016001871A1 (es) | Anticuerpos humanos para pd-1 | |
| EA201891209A1 (ru) | Модуляторы хемокиновых рецепторов | |
| UY37134A (es) | Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4 | |
| CL2018000687A1 (es) | Nuevos compuestos bicíclicos como inhibidores de atx. | |
| CL2016002021A1 (es) | Ciclopropilaminas como inhibidores lsd1. | |
| BR112016029076A8 (pt) | Modulação de atividade de complemento | |
| MX375352B (es) | Reguladores de nrf2. | |
| UY37018A (es) | Inhibidores bicíclicos de pad4 | |
| MX381046B (es) | Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas. | |
| DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| UY36175A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| CL2014002661A1 (es) | Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer. | |
| UY37017A (es) | Inhibidores aza-bencimidazol de pad4 | |
| CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. | |
| CL2016002084A1 (es) | Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina. | |
| CL2016002515A1 (es) | Quinazolin-thf-aminas halogenadas como inhibidores de pde1. | |
| BR112017006552A2 (pt) | composições e métodos para inibir a atividade biológica de biomoléculas solúveis | |
| EP3542777A4 (en) | MEDICINAL COMPOSITION FOR ROOT CANAL |